newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

  • Aprea Therapeutics President and CEO Oren Gilad, Ph.D. will participate in a fireside chat at Guggenheim's 3rd Annual Healthcare Innovation Conference.
  • The conference is scheduled for November 9-11, 2026, in Boston, MA.
  • Dr. Gilad's specific presentation is set for Monday, November 9, 2026, at 10:00 am ET.
  • A webcast link is available for the event, while one-on-one meetings require contacting a Guggenheim representative.
  • Aprea is a clinical-stage oncology company developing targeted therapies that aim to minimize toxicity by exploiting cancer cell mutation vulnerabilities.
  • The company's lead clinical programs include APR-1051, a WEE1 kinase inhibitor, & ATRN-119, an ATR inhibitor, both targeting solid tumors.
  • Potential applications for Aprea's technology span ovarian, colorectal, prostate, & breast cancers.
  • The company directs investors & media to its investor relations website for material nonpublic information & uses designated contacts for inquiries.
Company
Aprea Therapeutics
Keywords
Nasdaq:APRE, Aprea Therapeutics